Analysts think AVXL stock price could increase by 579%
Aug 08, 2024, 6:25 AM
-8.88%
What does AVXL do
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company based in New York, develops therapeutics for neurodegenerative and neurodevelopmental disorders, utilizing precision medicine and genomic data to identify biomarkers. Its lead compound, ANAVEX 2-73, targets Alzheimer’s, Parkinson’s, and other CNS diseases, including Rett syndrome.
6 analysts think AVXL stock price will increase by 578.52%. The current median analyst target is $41.25 compared to a current stock price of $6.08. The lowest analysts target is $15.15 and the highest analyst target is $48.30.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.